SCHEMBL1394755

SCHEMBL1394755

Cc1cc(N2CCNC(C)(C)C2)nn2c(-c3ccnc4[nH]ccc34)c(-c3ccc(F)cc3)nc12

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CSNK1E P49674 6/20 0.50
MAPK14 Q16539 8/20 0.46
CSNK1D P48730 5/20 0.43
MAPK11 Q15759 1/20 0.43
CSNK1A1 P48729 1/20 0.38
CSNK1A1L Q8N752 1/20 0.38
EGFR P00533 2/20 0.38
AURKA O14965 1/20 0.35
FLT3 P36888 1/20 0.35
AURKB Q96GD4 1/20 0.35
ROCK2 O75116 1/20 0.35
LATS1 O95835 1/20 0.34
RPS6KA3 P51812 1/20 0.34
GRIA1 P42261 2/20 0.34
PRKD1 Q15139 1/20 0.33
PRKD2 Q9BZL6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1394773 0.92 CSNK1E (0.44) CSNK1EMAPK14CSNK1DMAPK11CSNK1A1
SCHEMBL1393779 0.90 MAPK14 (0.42) CSNK1EMAPK14CSNK1DMAPK11CSNK1A1
SCHEMBL1394140 0.87 CSNK1E (0.68) CSNK1EMAPK14CSNK1DMAPK11CSNK1A1
SCHEMBL1394117 0.84 MAPK14 (0.46) CSNK1EMAPK14CSNK1DMAPK11CSNK1A1
SCHEMBL3115650 0.82 CSNK1E (0.73) CSNK1EMAPK14CSNK1DMAPK11LATS1
SCHEMBL1393692 0.82 MAPK14 (0.47) CSNK1EMAPK14CSNK1DMAPK11CSNK1A1
SCHEMBL1393694 0.82 MAPK14 (0.47) CSNK1EMAPK14CSNK1DMAPK11CSNK1A1
SCHEMBL1394354 0.81 MAPK14 (0.46) CSNK1EMAPK14CSNK1DMAPK11CSNK1A1
SCHEMBL1394907 0.81 MAPK14 (0.46) CSNK1EMAPK14CSNK1DMAPK11CSNK1A1
SCHEMBL1395235 0.80 MAPK14 (0.45) CSNK1EMAPK14CSNK1DMAPK11CSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2370446-B1 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-B]PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES,PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-11-25 EP claimed
US-8546395-B2 6-cycloamino-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-10-01 US claimed
US-20120010208-A1 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 US claimed
EP-2370446-B1 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-B]PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES,PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-11-25 EP disclosed
US-8546395-B2 6-cycloamino-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-10-01 US disclosed
US-20120010208-A1 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010208-A1 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CBR3, CBR1, CNR1 CSNK1E 2042/4885MAPK14 4289/4885CSNK1D 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.